secwatch.observer — SEC 8-K summary
======================================

Issuer:     Milestone Pharmaceuticals Inc. (MIST)
CIK:        0001408443
Form:       8-K
Filed at:   2025-05-14T23:59:59+00:00
Accession:  0001104659-25-048160
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Milestone Pharma Q1 net loss $20.8M; CRL issues unresolved; Type A meeting requested
--------------------------------------------------------------------------------

- Q1 net loss $20.8M vs $10.4M YoY; no revenue; cash $56.0M down from $69.7M.
- FDA CRL for CARDAMYST (etripamil) in PSVT cites nitrosamine impurities and facility GMP issues.
- Type A meeting requested with FDA to address CMC concerns; no clinical safety/efficacy issues.
- New USPTO method-of-use patent extends etripamil IP protection to July 2042.
- Phase 3 AFib-RVR enrollment paused to prioritize CRL resolution; commercial ramp temporarily halted.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1408443/000110465925048160/0001104659-25-048160-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1408443/000110465925048160/tm2515019d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-048160

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer